Last reviewed · How we verify

Gingivitis — Treatment Landscape & Competitive Intelligence

Gingivitis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gingivitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Exidine CHLORHEXIDINE Molnlycke Hlth chlorhexidine Solute carrier family 22 member 1 1976-01-01
Chlorhexidin Chlorhexidin Krishnadevaraya College of Dental Sciences & Hospital Synaptojanin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Krishnadevaraya College of Dental Sciences & Hospital · 1 drug in Gingivitis
  2. Molnlycke Hlth · 1 drug in Gingivitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gingivitis:

Cite this brief

Drug Landscape (2026). Gingivitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gingivitis. Accessed 2026-06-09.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing